trial

12 Week Open, Non-Comparative Switch Study Of Oral Ziprazidone In Previously Treated Schizophrenic Patients

NCTId NCT00159757
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 4 · Terminated
Enrollment 150
Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 4
Status
Terminated
Enrollment
150
Study type
Interventional
Allocation
Non Randomized
Model
Single Group
Masking
None
Start
2003-11
Primary completion
—
Eligibility
ALL · 18 Years

Interventions & indications

Drugs
ziprazidone

Sponsors

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.Lead Sponsor

Sites

8 total
Budapest, HungaryDebrecen, HungaryEsztergom, HungaryKecskemét, HungaryKistarcsa, HungaryPécs, HungarySzékesfehérvár, HungaryTatabánya, Hungary

Facts & assertions

3 sourced
Enrollment
150
Phase
PHASE4
Status
TERMINATED
relationships
The graph out of here
drug
ziprazidone
drug
lead_sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
company
indication
Schizophrenia
indication
Schizophrenia
indication